Post #2 by LucidDreamer on the Esperion Therapeutics board

Stocks A to Z / Stocks E / Esperion Therapeutics (ESPR)

Unthreaded | Threaded | Whole Thread (10)

Post New | Post Reply | Report Post | Recommend It!

No. of Recommendations: 5

https://www.esperion.com/news-releases/news-releas...

Today's PR illustrates the ongoing adoption and improved coverage (cost and in some/most cases of not needing prior authorization from a cardiologist) that will be key to sales growth.

Similar to how improvements occurred in June at end of Q2, this improvement is occurring in Sept at end of Q3.
Q3 numbers should be decent. I am forecasting $33-35m in US sales only.

Q4 could see an inflection to the $40m range. That would be 100% y/y growth and really drive home the idea that this has now entered hyper-growth and my contention is that being viewed as a growth stock will cause a re-rating of the stock in terms of multiple/valuation.

Will see.

Dreamer

Post New | Post Reply | Report Post | Recommend It!

Print the post

Unthreaded | Threaded | Whole Thread (10)

Prev | Next

Announcements

Esperion Therapeutics FAQ

Contact Shrewd'm
Contact the developer of these message boards.

A community forum supporting civilized, and highly helpful, self-educating investors that come together for Shrewdness and merry spirits. These message boards closely follow the look and feel of the old message boards at boards.fool.com prior to the boards redirected to discussion.fool.com. Shrewd'm is not affiliated with the comprehensive and excellent investment website, The Motley Fool (TMF), in any way. The Shrewd commmunity here has owed, and continues to owe, gratitude to The Motley Fool for nurturing a culture of jovial irreverence towards Wall St, and that tradition will continue here.